Key Insights

Highlights

Treatment Research

14 treatments under study, led by Pegaspargase

Research Leaders

10 sponsors active, led by Sun Yat-sen University

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Phase 2 (4)
Phase 3 (1)

Trial Status

Unknown3
Active Not Recruiting1
Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT04127227Phase 2Active Not RecruitingPrimary

Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type

NCT04365036Phase 3RecruitingPrimary

A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

NCT05316246Phase 2UnknownPrimary

Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma

NCT04484506Phase 2UnknownPrimary

Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma

NCT04231370Phase 2UnknownPrimary

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

Showing all 5 trials

Research Network

Common Treatments

  • Pegaspargase2
  • Pegaspargase Cyclophosphamide Vincristine Etoposide Prednisone1
  • Sintilimabpegaspargasegemcitabineoxaliplatin1
  • Vincristine1
  • Lenalidomide1

Active Sponsors

  • Sun Yat-sen University2
  • Jiangxi Provincial Cancer Hospital1
  • Beijing Tongren Hospital1
  • Peking University International Hospital1
  • Hebei Medical University Fourth Hospital1

Top Investigators

Activity Timeline